Pdt Partners, LLC Adagio Therapeutics, Inc. Transaction History

Pdt Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.54 - $4.52 $89,377 - $159,049	-35,188 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.81 - $10.77 $18,409 - $52,040	4,832 Added 15.92%	35,188 $160,000
Q4 2021 Feb 14, 2022	BUY	$6.35 - $47.04 $192,760 - $1.43 Million	30,356 New	30,356 $220,000

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.